Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Real-time Estimate Cboe BZX  -  01:17:09 2023-01-27 pm EST
253.06 USD   -0.71%
07:49aBristol Myers Gets CHMP Backing for Sotyktu, Reblozyl
DJ
01/26Amgen announces webcast of 2022 fourth quarter and full year financial results
PR
01/26Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Announces Appointment of S. Omar Ishrak to its Board of Directors

07/29/2021 | 07:10pm EST

Amgen announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Compensation and Management Development Committee, effective July 30, 2021. Dr. Ishrak served as chairman and chief executive officer of Medtronic plc, a global medical technology company, from 2011 to 2020. During his tenure, Medtronic launched numerous innovative products, expanded geographically, completed several strategic acquisitions, and strengthened its commitment to social responsibility. Prior to joining Medtronic, Dr. Ishrak held numerous leadership positions at GE Healthcare, serving as president and chief executive officer of GE Healthcare Systems, GE Healthcare Clinical Systems, and GE Healthcare Ultrasound in his more than 15 years with the company. Dr. Ishrak has been a director of Intel Corporation since 2017 and was named chairman of the board in January 2020. Dr. Ishrak has served as chairman of the board of Compute Health Acquisition Corporation, a special purpose acquisition company, since January 2021. Dr. Ishrak also serves on the Board of Directors of the Cleveland Clinic and is a member of the Board of Trustees of the Asia Society, an educational organization dedicated to promoting mutual understanding and strong partnerships between Asia and the U.S. Since May 2021, Dr. Ishrak has been a senior advisor to Blackstone Life Sciences, a segment of the Blackstone Group Inc. that invests in the biopharmaceutical and medical technology industries to advance new treatments for patients.


ę S&P Capital IQ 2021
All news about AMGEN INC.
07:49aBristol Myers Gets CHMP Backing for Sotyktu, Reblozyl
DJ
01/26Amgen announces webcast of 2022 fourth quarter and full year financial results
PR
01/26Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals
RE
01/24Rule 17 Announcement - Horizon Therapeutics plc
AQ
01/19Piper Sandler Adjusts Amgen's Price Target to $293 From $299, Keeps Overweight Rating
MT
01/19Four New Indications for BeiGene's Tislelizumab Included in China's Expanded National R..
MT
01/18Barclays Adjusts Price Target on Amgen to $240 From $234, Maintains Underweight Rating
MT
01/16Exploring The Amgen Genus Claims Headed To High Court
AQ
01/13Drug companies favor biotech meds over pills, citing new U.S. law
RE
01/13North American Morning Briefing: Big Day For Bank -2-
DJ
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 241 M - -
Net income 2022 6 490 M - -
Net Debt 2022 26 743 M - -
P/E ratio 2022 21,2x
Yield 2022 3,04%
Capitalization 136 B 136 B -
EV / Sales 2022 6,20x
EV / Sales 2023 5,91x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Last Close Price 254,88 $
Average target price 268,00 $
Spread / Average Target 5,15%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-2.32%135 999
JOHNSON & JOHNSON-4.04%441 560
ELI LILLY AND COMPANY-4.40%330 671
NOVO NORDISK A/S0.14%309 711
ROCHE HOLDING AG-0.52%277 411
MERCK & CO., INC.-3.68%270 958